See more : Stellar Capital Services Limited (STELLAR.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Aeglea BioTherapeutics, Inc. (AGLE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aeglea BioTherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Glanbia plc (GLAPF) Income Statement Analysis – Financial Results
- Tuscan Holdings Corp. II (THCA) Income Statement Analysis – Financial Results
- MegaChips Corporation (6875.T) Income Statement Analysis – Financial Results
- GeneDx Holdings Corp. (WGS) Income Statement Analysis – Financial Results
- BigBen Interactive (0O0E.L) Income Statement Analysis – Financial Results
Aeglea BioTherapeutics, Inc. (AGLE)
About Aeglea BioTherapeutics, Inc.
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.33M | 18.74M | 0.00 | 0.00 | 3.89M | 5.21M | 4.63M | 6.09M | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.33M | 18.74M | 0.00 | 0.00 | 3.89M | 5.21M | 4.63M | 6.09M | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 58.58M | 57.07M | 59.64M | 64.60M | 36.72M | 22.82M | 18.14M | 11.45M | 6.83M |
| General & Administrative | 28.53M | 27.32M | 21.84M | 15.73M | 12.63M | 10.07M | 8.39M | 5.95M | 2.07M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.53M | 27.32M | 21.84M | 15.73M | 12.63M | 10.07M | 8.39M | 5.95M | 2.07M |
| Other Expenses | -7.00K | -122.00K | -5.00K | -63.00K | -57.00K | -42.00K | -36.00K | -2.00K | 0.00 |
| Operating Expenses | 87.11M | 84.39M | 81.48M | 80.33M | 49.35M | 32.88M | 26.53M | 17.40M | 8.90M |
| Cost & Expenses | 87.11M | 84.39M | 81.48M | 80.33M | 49.35M | 32.88M | 26.53M | 17.40M | 8.90M |
| Interest Income | 837.00K | 111.00K | 593.00K | 2.14M | 1.17M | 482.00K | 244.00K | 22.00K | 1.00K |
| Interest Expense | 837.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.57M | 1.58M | 996.00K | 418.00K | 293.00K | 249.00K | 132.00K | 89.00K | 19.00K |
| EBITDA | -84.78M | -65.65M | -80.49M | -80.33M | -44.06M | -27.68M | -21.77M | -11.23M | -7.44M |
| EBITDA Ratio | -3,640.23% | -350.33% | 0.00% | 0.00% | -1,133.10% | -531.72% | -470.48% | -184.49% | 0.00% |
| Operating Income | -84.78M | -65.65M | -81.48M | -80.33M | -45.46M | -27.68M | -21.91M | -11.32M | -8.90M |
| Operating Income Ratio | -3,640.23% | -350.33% | 0.00% | 0.00% | -1,169.32% | -531.72% | -473.34% | -185.95% | 0.00% |
| Total Other Income/Expenses | 830.00K | -11.00K | 588.00K | 2.08M | -57.00K | -42.00K | -36.00K | 20.00K | -1.44M |
| Income Before Tax | -83.95M | -65.66M | -80.89M | -78.25M | -44.35M | -27.24M | -21.70M | -11.30M | -10.35M |
| Income Before Tax Ratio | -3,604.59% | -350.39% | 0.00% | 0.00% | -1,140.64% | -523.27% | -468.84% | -185.62% | 0.00% |
| Income Tax Expense | -136.00K | 141.00K | -593.00K | -2.56M | -57.00K | -731.00K | -244.00K | -22.00K | 1.44M |
| Net Income | -83.82M | -65.80M | -80.30M | -75.69M | -44.35M | -27.24M | -21.70M | -11.30M | -10.35M |
| Net Income Ratio | -3,598.75% | -351.14% | 0.00% | 0.00% | -1,140.64% | -523.27% | -468.84% | -185.62% | 0.00% |
| EPS | -24.86 | -25.02 | -37.61 | -59.23 | -53.25 | -45.01 | -55.40 | -24.71 | -37.93 |
| EPS Diluted | -24.86 | -25.02 | -37.61 | -59.23 | -53.25 | -45.01 | -55.40 | -24.71 | -37.93 |
| Weighted Avg Shares Out | 3.37M | 2.63M | 2.13M | 1.28M | 832.90K | 605.13K | 391.67K | 457.19K | 272.80K |
| Weighted Avg Shares Out (Dil) | 3.37M | 2.63M | 2.13M | 1.28M | 832.90K | 605.13K | 391.67K | 457.19K | 272.80K |
10 Top Penny Stocks To Watch Under $1
Travere: Pegtibatinase Takes The Lead In The HCU Treatment Race
Penny Stocks to Buy Now? 7 Under $1 To Watch This Week
3 Top Penny Stocks Under $1 To Watch Before Next Week
Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Fails
Aeglea (AGLE) Moves to Buy: Rationale Behind the Upgrade
Best Penny Stocks To Buy Now That CPI Is Out? 4 To Watch Before Next Week
Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue Estimates
4 Penny Stocks To Buy According To Analysts Right Now
Why Are Penny Stocks Volatile? 3 Reasons and How to Profit
Source: https://incomestatements.info
Category: Stock Reports